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Québec, Quebec, Canada
Objectives This study sought to identify the clinical and metabolic determinants of bioprosthetic valve degeneration.
Background Structural valve degeneration (SVD) is the major cause of bioprosthetic valve failure. Recent retrospective stud-
ies have reported an association between atherosclerotic risk factors and development of SVD.
Methods A total of 203 consecutive patients with aortic bioprosthetic valves were recruited. Doppler echocardiography
and multidetector computed tomography (CT) examinations were performed for assessment of bioprosthesis
calcification and abdominal adiposity. A cardiometabolic risk profile was also obtained. SVD was defined as
an increase in mean transprosthetic gradient of 10 mm Hg and/or a worsening of transprosthetic regurgi-
tation 1/3 class between 1-year post-operative echo and last follow-up echo (mean follow-up time was
8  3 years).
Results Forty-two patients (20%) were identified as developing SVD. Patients with SVD had significantly higher plasma
total-cholesterol (4.6  1.1 mmol/l vs. 4.1  0.9 mmol/l, p  0.05), low-density lipoprotein-cholesterol (2.5 
1.0 mmol/l vs. 2.2  0.7 mmol/l, p  0.02), and apolipoprotein B (ApoB) levels (0.71  0.22 g/l vs. 0.64 
0.17 g/l, p  0.02) and higher ApoB/ApoA-I ratios (0.48  0.17 vs. 0.41  0.11, p  0.004) than those with no
SVD. Multivariate analysis revealed that increased ApoB/ApoA-I ratio (odds ratio [OR]: 1.41, 95% confidence in-
terval [CI]: 1.10 to 1.82 per 0.1 increment; p  0.007) and the use of bisphosphonates (OR: 3.57, 95% CI: 1.14
to 10.80 p  0.02) were the strongest independent predictors of SVD.
Conclusions This is the first study to report a strong association between increased ApoB/ApoA-I ratio and the risk of devel-
oping SVD among patients with aortic bioprosthetic valves. Further studies are needed to determine if an ele-
vated ApoB/ApoA-I ratio, which reflects the balance of proatherogenic and antiatherogenic lipoproteins, is a risk
marker or a risk factor for SVD. (J Am Coll Cardiol 2013;61:752–61) © 2013 by the American College of
Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.033Approximately 275,000 prosthetic valves are implanted each
year worldwide, one-half of which are mechanical and half
are bioprosthetic valves, with a shift toward greater use of
bioprostheses (BPVs) over the last decade (1). BPVs gen-
erally have a good hemodynamic profile and, unlike me-
chanical valves, have a low thrombogenic potential and
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However, BPVs are still plagued by their limited durability
(1,2). Structural valve degeneration (SVD) is the major
cause of bioprosthetic valve failure (3,4). SVD is expressed
clinically by the development of a progressive stenosis due to
leaflet calcification or by regurgitation due to leaflet tear.
Reoperation rates for SVD of BPVs have been shown to be
as high as 30% at 15 years (4). For years, SVD was seen as
a passive degenerative process of calcification related to the
chemical fixative treatment of porcine or bovine tissue
before implantation, which is accelerated by mechanical
stress (1). Recent studies have reported similarities between
histological findings in native aortic stenosis valves and
BPVs explanted for SVD such as the presence of lipids,
foam cells, and inflammation (5,6). There is compelling
evidence that aortic stenosis is an active disorder involving
atherosclerotic-like processes (7–10). Similarly, it has been sug-
gested that atherosclerotic risk factors may influence the develop-
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shown an association between some atherosclerotic risk factors
such as diabetes, smoking, hypercholesterolemia, and meta-
bolic syndrome and the development of SVD (11–13). These
results suggest that atherosclerotic-like processes could also
contribute to the pathogenesis of SVD. Identification of modifi-
able risk factors of SVD is an essential first step in the develop-
ment of medical therapies that could inhibit or at least slow the
progression of SVD, especially if initiated at the time of surgery,
before the onset of BPV tissue degeneration. The objective of the
present study was to identify the clinical and metabolic correlates
of bioprosthetic SVD assessed by Doppler echocardiography.
Methods
Study patients. From June 2008 to June 2010, 203 con-
secutive patients with a BPV in the aortic position were
prospectively recruited for this study that included a Dopp-
ler echocardiography, a multislice computed tomography
(CT) examination, and a blood sample analysis. All patients
underwent an isolated aortic valve replacement procedure at
the Quebec Heart and Lung Institute at least 3 years
previously, with a complete Doppler echocardiographic
examination available at 12  6 months post-operatively
labeled “1-year post-op. Echo” hereafter). Exclusion crite-
ia were: 1) presence of mild or increased paravalvular
egurgitation; 2) significant concomitant mitral valve dis-
ase, defined by mild or increased mitral regurgitation or
itral valve effective orifice area (EOA) 1.5 cm2; 3)
ubvalvular flow acceleration precluding measurement of
PV valve EOA; 4) left ventricular (LV) systolic dysfunc-
ion, defined by an LV ejection fraction of 50%; and 5)
ongestive heart failure with New York Heart Association
lass III or IV. All patients recruited to the study had a
linical examination, a complete plasma glycemic and lipid
rofile, and a complete Doppler echocardiographic study
labeled “last follow-up echo” hereafter). Patients also had a
ultidetector CT scan for assessment of BPV calcification
nd for abdominal subcutaneous and visceral adiposity.
chocardiographic measurements. All Doppler echocar-
iographic studies were reviewed by the same cardiologist
H.M.). Operators were blinded to the results of clinical,
aboratory, and CT data. Peak transprosthetic flow velocity
as determined by continuous-wave Doppler. Mean trans-
rosthetic gradient was calculated using the modified Ber-
oulli equation. BPV EOA was calculated using the stan-
ard continuity equation. The absolute and annualized
hanges in mean gradient and EOA were calculated as:
bsolute change  (value at last follow-up echo – value at
-year post-op echo); annualized change  (value at last
ollow-up echo – value at 1-year post-op echo)/time be-
ween 1 year and last follow-up echocardiographic exami-
ations, respectively.
Prosthetic regurgitation was detected by color Doppler
chocardiography, and the origin of the jet was visualized in
everal views to differentiate periprosthetic from transpros-hetic regurgitation. Transpros-
hetic regurgitation severity was
ssessed as recommended by the
merican Society of Echocardi-
graphy and classified as mild,
oderate, or severe (14). Wors-
ning of valve regurgitation was
efined as an increase of at least
ne-third of the class in the se-
erity of regurgitation during
ollow-up according to the fol-
owing scheme: from none or
ild to moderate or from mod-
rate to severe.
SVD was defined as an in-
rease in transprosthetic mean
radient 10 mm Hg and/or
orsening of transprosthetic re-
urgitation 1/3 class between
-year and last follow-up echo-
ardiograms. Prosthesis-patient
ismatch (PPM) was defined as not clinically significant
i.e., mild or no PPM) if the indexed EOA was 0.85
m2/m2, moderate if it was 0.65 cm2/m2 and 0.85
cm2/m2, and severe if it was 0.65 cm2/m2.
Clinical and operative data. Medical history included
history of smoking, documented diagnoses of hypertension
(patients receiving antihypertensive medications or having
known but untreated hypertension [blood pressure140/90
mm Hg]), diabetes (fasting glucose 7 mmol/l), hypercho-
lesterolemia (patients receiving cholesterol-lowering medi-
cation or, in the absence of such medication, having a total
plasma cholesterol level 240 mg/l), coronary heart disease
(history of myocardial infarction or coronary artery stenosis
on coronary angiography), renal insufficiency (estimated
glomerular filtration rate 60 ml/min/1.73 m2), and de-
tailed information on current medication were collected.
Body weight, height and waist circumference were mea-
sured following standardized procedures. Blood pressure,
heart rate and NYHA class were also assessed. The clinical
identification of patients with the features of the metabolic
syndrome was based on the modified criteria proposed by
the National Cholesterol Education Program Adult Treat-
ment Panel III (NCEP-ATP III) (15). Operative data
including model and size of BPVs were also recorded.
Laboratory data. Blood was obtained by venipuncture after
patients fasted overnight. Plasma was isolated and immedi-
ately processed by the laboratory for the measurement of
glucose, insulin, total cholesterol (total-C), high-density
lipoprotein-cholesterol (HDL-C), and triglyceride (TG)
levels. Low-density lipoprotein-cholesterol (LDL-C) was
calculated with the Friedewald formula when TG levels
were 5.0 mmol/l (16). No patient had TG levels 5.0
mmol/l. Plasma apolipoprotein A-I (ApoA-I) and apolipo-
protein B (ApoB) concentrations were measured using a
Abbreviations
and Acronyms
ApoA-I  apolipoprotein A-I
ApoB  apolipoprotein B
BPV  bioprosthetic valve
CT  computed
tomography
EOA  effective orifice
area
HDL-C  high-density
lipoprotein-cholesterol
LDL-C  low-density
lipoprotein-cholesterol
LV  left ventricular
MG  mean transprosthetic
gradient
SVD  structural valve
degeneration
TG  triglycerides
Total-C  total cholesterolnephelometric method with polyclonal antibodies on a
c
p
l
f
w
c
t
S
i
t
u
e
p
R
C
r
S
e
g
m
7
m
0
v
754 Mahjoub et al. JACC Vol. 61, No. 7, 2013
ApoB/ApoA-I Ratio and Bioprosthesis Degeneration February 19, 2013:752–61BN-Prospect machine (Dade-Behring) (17). Distribution
of LDL particle sizes was determined by nondenaturing 2%
to 16% polyacrylamide gradient gel electrophoresis (18).
The relative proportion of small LDL particles was deter-
mined by computing the relative area of the densitometric
scan corresponding to LDL particles255 Å. The absolute
concentration of cholesterol among small LDL particles was
calculated by multiplying plasma LDL-C levels by the
relative proportion of small LDL particles. The homeostatic
assessment model (HOMA) index was calculated to assess
insulin resistance. C-reactive protein, creatinine levels, cal-
cemia, and phosphatemia were also measured.
Multidetector CT data. BPV leaflet calcification was
quantified by multidetector CT with the use of the volu-
metric method that identifies calcium within the BPV
leaflets as areas of at least two contiguous pixels with a
density 130 HU as previously described (19). The volume
of calcified tissue expressed in cubic millimeters was indi-
vidually calculated by summing the lesion volumes for all
sections containing calcium. Particular attention was paid to
distinguishing calcifications located in the region of the
BPV leaflets from those located in the region of the
prosthesis sewing ring and aortic annulus. Cross-sectional
areas of abdominal total, visceral, and subcutaneous adipose
tissue were also assessed by CT using previously described
procedures (20). Operators were blinded to the results of
echocardiograms.
Statistical analyses. Continuous data were expressed as
mean  SD or median and interquartile ranges (IQR) and
were compared using unpaired Student’s t test or a Wil-
oxon rank sum test. Categorical data were expressed as a
ercentage and compared with the chi-square test. A
ogarithmic transformation was used when variables did not
ollow a normal distribution. Correlations between variables
ere determined using linear regressions or Spearman’s
oefficients. A multiple logistic regression analysis was used
o identify the factors independently associated with BPV
VD. A multiple linear regression was used to identify the
ndependent predictors of the progression rate of transpros-
hetic mean gradient. Variables with p values of 0.1 on
nivariate analysis were entered into the multivariate mod-
ls. Age at implantation was forced into the models. A
value of 0.05 was considered statistically significant.
esults
linical and operative data. Among the 203 patients
ecruited to the study, 42 (20%) were classified as having
VD by Doppler echocardiography. Table 1 compares
patients with SVD with those with no SVD, with respect to
clinical and operative data. The follow-up time was signif-
icantly (p  0.03) longer in the SVD group (9  4 years)
than in the No SVD group (7  3 years). There were no
significant differences between the two groups in terms of
age at implantation, sex, and cardiovascular risk factors
(Table 1). Of the 203 patients, 90 patients (44%) met theclinical criteria of the metabolic syndrome with 22 patients
(52%) in the SVD group and 68 patients (42%) in the No
SVD group (p  0.2). Moreover, there was no significant
difference between the two groups in terms of medical
therapy such as statins (p  0.1), angiotensin-converting
enzyme inhibitors (p  0.4), and angiotensin receptor
blockers (p  0.5). However, a significantly greater propor-
tion of patients took bisphosphonates in the SVD group
than in the No SVD group (18% vs. 11%; p  0.04). As for
operative data, there was no difference between groups
regarding type of BPV (porcine vs. bovine or stentless vs.
stented), prosthesis size, use of Teflon-felt pledgets for BPV
suture, or prevalence of PPM. There was a borderline
significant trend (p  0.05) for higher proportion of
concomitant coronary artery bypass graft at the time of valve
replacement surgery in the SVD group.
Doppler echocardiographic and CT data. SVD was asso-
ciated with an increase in gradient in 81% of cases (36 patients),
and only 8 patients (19%) had diagnoses of SVD related to
a worsening of valve regurgitation. Among these 8 patients,
4 had moderate valve regurgitation at last follow-up echo-
cardiography, whereas 4 patients had a severe valve regur-
gitation caused by a leaflet tear with an indication for urgent
aortic valve replacement. One of these 4 patients died
immediately after surgery due to cardiogenic shock.
As expected, patients in the SVD group had higher mean
transprosthetic gradient (24  7 mm Hg vs. 12  5 mm Hg;
p  0.0001), peak gradient (44  13 mm Hg vs. 25  10
mm Hg; p  0.0001), peak transprosthetic velocity (3.25 
0.5 m/s vs. 2.44  0.5 m/s; p  0.0001), and lower EOA
(0.97  0.36 cm2 vs. 1.36  0.4 cm2, p  0.0001) at last
chocardiography follow-up than patients in the No-SVD
roup (Table 2). The average absolute progression rate of
ean gradient was 12.4  5 mm Hg vs. 0.71  4 mm Hg
(p 0.0001), and the average annualized progression rate of
mean gradient was 1.9  1.6 (median: 1.38; IQR: 0.91 to
2.49) mm Hg/year versus 0.09  0.6 (median: 0.11, IQR:
0.31 to 0.39) mm Hg/year (p  0.0001), respectively, in
the SVD versus No SVD groups, respectively. Furthermore,
patients with SVD had significantly higher calcium deposit
within the BPV leaflets, assessed by CT (181  33 mm3 vs.
5  37 mm3; p  0.0001).
Metabolic profile of patients with bioprosthetic valve
degeneration. Patients with SVD had significantly higher
plasma levels of total-C (4.6  1.1 mmol/l vs. 4.1  0.9
mol/l; p  0.05), LDL-C (2.53  1.0 mmol/l vs. 2.21 
.7 mmol/l, p  0.02), non–HDL-C (3.22  1.09 mmol/l
s. 2.82 0.85 mmol/l, p 0.01), ApoB (0.71 0.2 g/l vs.
0.64 0.1 g/l, p 0.02), and concentration of LDL-C255 Å
(0.66  0.56 mmol/l vs. 0.55  0.34 mmol/l, p  0.03) than
patients without SVD (Table 3). The ApoB/ApoA-I and the
total-C/HDL-C ratios were also significantly higher in
patients with SVD (0.48  0.17 vs. 0.41  0.11, p  0.004
and 3.65  1.3 vs. 3.2  0.8, p  0.04 respectively).
Moreover, a higher HOMA index (3.9  5.9 vs. 2.9  2.6,
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group.
Predictors of bioprosthetic valve degeneration. On uni-
variable analysis, SVD was associated with longer follow-up
duration (p 0.03) and with higher plasma levels of total-C
(p  0.05), LDL-C (p  0.02), non–HDL-C (p  0.01),
and ApoB (p  0.02), higher total-C/HDL-C ratio (p 
0.04), higher ApoB/ApoA-I ratio (p  0.004), and use of
bisphosphonate therapy (p  0.04) (Tables 1 and 3). On
multivariable analysis, the strongest independent predictors
of SVD were the ApoB/ApoA-I ratio (odds ratio [OR]:
1.41, 95% confidence interval [CI]: 1.10 to 1.82 per 0.1
increment; p  0.007), and the use of bisphosphonates
(OR: 3.57, 95% CI: 1.14 to 10.80 p 0.02) (Fig. 1). When
statin therapy was forced into the multivariate model, it did
not reach statistical significance (OR  0.91, 95% CI: 0.38
to 2.26, p  0.8) and ApoB/ApoA-I ratio (OR: 1.39, 95%
CI: 1.06 to 1.84 per 0.1 increment; p  0.01), as well as the
use of bisphosphonates (OR: 3.56, 95% CI: 1.14 to 10.79;
p  0.02) remained significant predictors of SVD. The use
of bisphosphonates remained independently associated with
SVD even after further adjustment for sex (OR: 3.62, 95%
Clinical and Operative DataTable 1 Clinical and Operative Data
Variables
All Patients (n 
(% of Total)
Age at implantation, yrs 67 8
Male 141 (69)
BMI, kg/m2 28 5
Follow-up time, yrs 8.0 3.4
Risk Factors
Hypertension 144 (71)
Diabetes 44 (21)
Obesity 56 (27)
History of hypercholesterolemia 156 (77)
Metabolic syndrome 90 (44)
Hx of smoking 124 (61)
CAD 97 (48)
Renal insufficiency 14 (7)
Medications
Statins 157(77)
ACE 63 (32)
ARB 56 (28)
Calcium 46 (23)
Vitamin D 41 (20)
Bisphosphonates 18 (9)
Operative data
Stented bioprosthesis 143 (70)
Porcine bioprosthesis 123 (60)
Bioprosthesis size, mm 23.9 2.2
Severe PPM (0.65 cm2/m2) 21 (11)
Pledgets 110 (58)
CABG 80 (39)
Values are mean  SD or n (% of n). *p values refer to comparisons b
ACE  angiotensin-converting enzyme; ARB  angiotensin recepto
CAD  coronary artery disease; PPM  prosthesis-patient mismatch;CI: 1.11 to 11.49, p  0.03). (When we used a linear regression multivariate model, the
independent predictors of higher progression rate of mean
transprosthetic gradient (in log-transformed format) were a
younger age at implantation (  0.03  0.01; p 
.008), a stented BPV (  0.97  0.29; p  0.001), and
igher ApoB/ApoA-I ratio (  1.47  0.65; p  0.02).
Correlates of ApoB/ApoA-I ratio. As ApoB/ApoA-I ra-
tio was the most powerful independent predictor of SVD,
we sought to determine which were the clinical and meta-
bolic factors associated with increased ApoB/ApoA-I ratio
in our study sample. ApoB/ApoA-I ratio was significantly
and positively associated with clinical diagnosis of the
metabolic syndrome (r  0.36; p  0.0001) and of hyper-
cholesterolemia (r  0.23; p  0.0009), with the HOMA
ndex (r  0.18, p  0.01) and with the CT cross-sectional
reas of total abdominal (r  0.21, p  0.006) and visceral
dipose (r 0.14, p 0.05) tissue (Table 4). There was also
significant negative correlation between ApoB/ApoA-I
atio and statin therapy (r  0.38; p  0.0001). On
ultivariable analysis, the metabolic syndrome (p 0.0001)
nd the absence of statin therapy (p  0.0001) were
ndependently associated with higher ApoB/ApoA-I ratio
No SVD
(n  161; 80%)
SVD
(n  42; 20%) p Value*
67 7 66 8 0.2
113 (70) 28 (66) 0.6
28 5 27 4 0.1
7.7 3 9.0 4 0.03
117 (72) 27 (64) 0.2
39 (24) 5 (12) 0.09
45 (28) 11 (26) 0.8
127 (79) 29 (69) 0.1
68 (42) 22 (52) 0.2
99 (61) 25 (59) 0.8
75 (46) 22 (52) 0.5
11 (7) 3 (7) 1.0
128 (79) 29 (69) 0.1
52 (33) 11 (27) 0.4
43 (27) 13 (31) 0.5
37 (23) 9 (23) 0.9
33 (20) 8 (20) 1.0
11 (7) 7 (18) 0.04
112 (69) 31 (74) 0.5
96 (59) 27 (64) 0.5
24 2.2 23.6 2.2 0.5
17 (10) 4 (9) 1.0
88 (58) 22 (58) 1.0
58 (36) 22 (52) 0.05
SVD and No SVD groups.
ers; BMI  body mass index; CABG  coronary artery bypass graft;
structural valve degeneration.203)
etweenTable 4). The ApoB/ApoA-I ratio remained an indepen-
iicular e
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ncrement; p  0.03) of SVD after adjustment for age,
duration of follow-up, and presence of metabolic syndrome
and diabetes.
Discussion
This prospective study reports that higher plasma levels of
LDL-C, non–HDL-C, and ApoB as well as higher ApoB/
ApoA-I and total-C/HDL-C ratios are significantly asso-
ciated with increased risk of SVD. Importantly, an increased
ApoB/ApoA-I ratio was found to be the most powerful
independent predictor of SVD. This novel finding sug-
gests that the proportion of LDL and HDL particles and
the ensuing dysregulation in cholesterol transport balance
could play a key role in the tissue degeneration of BPVs.
Doppler Echocardiographic and CT dataTable 2 Doppler Echocardiographic and CT
Variables All Patients (n  20
Echocardiographic data
Mean gradient
Early post-operative, mm Hg 11.8 5
Last follow-up, mm Hg 15 7
Progression, mm Hg 3.1 6
Progression rate, mm Hg/yr‡ 0.47 1.2
Median 0.21
Interquartile range 0.18–0.89
EOA
Early post-operative, cm2 1.55 0.38
Last follow-up, cm2 1.28 0.4
Progression, cm2 0.26 0.36
Progression rate, cm2/yr 0.03 0.05
Regurgitation
Early post-operative
None or mild 203 (100)
Moderate 0
Severe 0
Last follow-up
None or mild 195 (96)
Moderate 4 (2)
Severe 4 (2)
Worsening of valve
regurgitation
8 (4)
LVEF, %
Early post-operative 63 8
Last follow-up 63 9
Systolic PAP, mm Hg
Early post-operative 28 8
Last follow-up 35 8
CT data
BPV leaflet calcification, mm3 98 36
Total adipose tissue, cm2 476 178
Visceral fat, cm2 211 93
Subcutaneous fat, cm2 267 108
Values are mean  SD or n (% of n). *p values refer to the compariso
rate of gradient was not normally distributed, median values and inte
BPV  bioprosthesis; EOA  effective orifice area; LVEF  left ventr
valve degeneration.These findings provide further support to the conceptthat an active lipid-mediated process is involved in SVD
and that this process is determined, in large part, by the
quality rather than the quantity of the LDL and HDL
particles.
Definition and prevalence of SVD. The incidence of
SVD is most often derived from the incidence of reopera-
tion for BPV failure. Several studies in large series of
patients have reported an SVD incidence of 10% to 30% at
10 years and 20% to 50% at 15 years (4,21,22). However,
this approach may substantially underestimate the real
incidence of SVD (12,23). Several patients may indeed die
before their failed BPV is replaced, and it cannot be
excluded that the BPV dysfunction might have contributed
directly or indirectly to a patient’s death. Furthermore, an
important proportion of patients with severe BPV dysfunc-
o SVD (n  161; 80%) SVD (n  42; 20%) p Value*
11.8 5 11.5 5 0.7
12 5 24 7 0.0001
0.71 4 12.4 5 0.0001
0.09 0.6 1.9 1.6 0.0001
0.11 1.48
0.31–0.39 0.91–2.49
1.55 0.37 1.52 0.41 0.6
1.36 0.4 0.97 0.36 0.0001
0.19 0.33 0.54 0.34 0.0001
0.02 0.05 0.07 0.05 0.0001
161 (100) 42 (100)
1.00 0
0 0
161 (100) 34 (81)
0.00010 4 (9.5)
0 4 (9.5)
0 8 (19) 0.0001
63 8 63 9 0.9
63 9 64 9 0.7
28 8 27 5 0.5
34 9 37 7 0.1
75 37 181 33 0.0001
476 166 477 174 0.9
208 90 223 105 0.4
271 111 253 97 0.3
een SVD and No SVD groups. ‡Given that the annualized progression
e ranges are also provided for this variable.
jection fraction; PAP  pulmonary arterial pressure; SVD  structuraldata
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rquartiltion may be denied surgery owing to advanced age and/or
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February 19, 2013:752–61 ApoB/ApoA-I Ratio and Bioprosthesis Degenerationsevere comorbidities. The presence of SVD may also affect
the quality of life of these patients and may contribute to the
occurrence of adverse events. Hence, it is probably more
accurate to define SVD on the basis of the development of
BPV hemodynamic dysfunction documented by Doppler
echocardiography. In the present study, the prevalence of
SVD identified by Doppler echocardiography was 20% at a
mean follow-up of 8 years. In previous studies where
Doppler echocardiography was used to identify SVD, Fla-
meng et al. reported an SVD incidence of 7% at a median
follow-up of 6 years (23), whereas other investigators
reported an incidence of 30% to 39% with no precise
information about the time duration since implantation
(12,24). Discrepancies among the SVD incidence rates
reported in those studies may be due to differences in the
Determinants of ApoB/ApoA-I Ratioin Univari ble and Multivariable AnalysisTable 4 Determinants of ApoB/ApoA-I Ratioin Univariable and Multivariable Analysis
Variables
Univariable
Analysis
Multivariable
Analysis
r p Value  p Value
Age at implantation (yrs) 0.09 0.1
Obesity 0.1 0.1
Waist circumference (cm) 0.12 0.09 —
Total adipose tissue (cm2) 0.21 0.006 —
Visceral fat (cm2) 0.14 0.05 —
Hypercholesterolemia 0.23 0.0009 —
Metabolic syndrome 0.36 0.0001 0.05 0.01 0.0001
HOMA index 0.18 0.01 0.02 0.01 0.08
Statin therapy 0.38 0.0001 0.07 0.01 0.0001
Laboratory DataTable 3 Laboratory Data
Variables
All Patients
(n  203)
Glycemia, mmol/l 5.8 1.5
Insulinemia, pmol/l 81 60
HOMA index 3.1 3.6
Triglycerides, mmol/l 1.4 0.76
Total cholesterol, mmol/l 4.2 0.9
HDL cholesterol, mmol/l 1.35 0.3
LDL cholesterol, mmol/l 2.28 0.84
Total cholesterol/HDL cholesterol ratio 3.29 0.95
Non-HDL cholesterol, mmol/l 2.90 0.91
ApoB, g/l 0.65 0.18
ApoA-I, g/l 1.54 0.27
ApoB/ApoA-I ratio 0.43 0.13
%LDL particles255 Å 25.4% 14.7
Concentration of LDL-C255 Å, mmol/l 0.55 0.37
Calcemia, mg/dl 2.35 0.09
Phosphatemia, mg/dl 1.03 0.15
Ca Ph product 2.45 0.39
Creatininemia, mol/l 96 36
CRP, g/l 3.9 8
Values are mean  SD. *p value refer comparisons between SVD and
%LDL particles 255 Å  percentage of small (255 Å) LDL partic
among small LDL particles; Ca Ph  calcium phosphorus; CRP  C-re
assessment; LDL  low-density lipoprotein; SVD  structural valve dewHOMA  homeostatic model assessment.Doppler echocardiographic parameters and criteria used to
define SVD as well as to differences in the average time
interval between the BPV implantation and the last echocar-
diographic follow-up. In the present study, we elected to define
SVD on the basis of an absolute increase in mean transprosthetic
gradient of 10 mm Hg and/or a worsening of at least one
lass of regurgitation between the 1-year and last follow-up
chocardiographic examinations. We used this definition
ecause it was clinically meaningful and it was well suited
or this study where the time between the 1-year and last
ollow-up echocardiographic examinations was highly vari-
ble from one patient to the other (3 to 18.6 years). Use of
he annualized change in mean gradient with a fixed
ut-point value (e.g., 3 mm Hg/year such as that used in
revious studies) to identify SVD would have been mislead-
ng in this context.
isk factors of SVD. Similar to observations of native
ortic valve stenosis, several retrospectives studies reported
n association between cardiovascular risk factors and SVD,
hus suggesting that atherosclerotic-like processes could be
nvolved in the degeneration of BPV tissues (11–13,22,25).
everal studies reported an association between increased
holesterol levels and SVD (13,25). Briand et al. (12) also
eported that patients with metabolic syndrome have faster
rogression of BPV degeneration as documented by Dopp-
er echocardiography. A large multicenter study (25) re-
ently reported that type 2 diabetes is a powerful predictor
f SVD and mortality in patients with aortic or mitral valve
eplacement with a BPV. However, those previous studies
No SVD
(n  161; 80%)
SVD
(n  42; 20%) p Value*
5.7 1.5 6 1.7 0.2
79 54 89 81 0.4
2.9 2.6 3.9 5.9 0.1
1.4 0.75 1.5 0.78 0.5
4.1 0.9 4.6 1.1 0.05
1.35 0.32 1.34 0.45 0.9
2.21 0.78 2.53 1.01 0.02
3.20 0.81 3.65 1.32 0.04
2.82 0.85 3.22 1.09 0.01
0.64 0.17 0.71 0.22 0.02
1.55 0.25 1.51 0.32 0.4
0.41 0.11 0.48 0.17 0.004
24.9% 14.6 27.4% 14.9 0.3
0.52 0.34 0.66 0.56 0.03
2.35 0.09 2.34 0.09 0.6
1.02 0.14 1.07 0.16 0.1
2.43 0.38 2.52 0.42 0.1
96 37 95 33 0.8
3.37 4.6 5.95 15 0.2
D groups.
ncentration of LDL-C255 Å  absolute concentration of cholesterol
protein; HDL  high-density lipoprotein; HOMA  homeostatic model
tion.No SV
les; coere retrospective and did not report the measures of the
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and ApoB/ApoA-I ratios.
In the present study, we found that several markers of
lipid metabolism, including LDL-C, non–HDL-C, ApoB,
and the ApoB/ApoA-I ratio were significantly associated
with higher incidences of SVD. Of interest, the most
powerful associations were found with ApoB levels and
ApoB/ApoA-I ratio. Total ApoB level largely reflects the
number of potentially atherogenic particles. ApoA-I is the
main protein in HDL particles and is involved in reverse
cholesterol transport. It has been suggested that the advan-
tage of ApoB/ApoA-I ratio relative to standard lipid mark-
ers such LDL-C or HDL-C is that it better reflects the
balance between concentrations of proatherogenic versus
antiatherogenic lipoprotein particles. This may explain why
the ApoB/ApoA-I ratio outperforms LDL-C as a predictor
of ischemic events and as an index of residual cardiovascular
risk, particularly in populations with LDL-C in the normal
or low abnormal ranges (26–30). The INTERHEART
study, a myocardial infarction case-control multicenter
study of 30,000 patients, reported that among all measured
cardiovascular risk factors including smoking, hypertension,
abdominal obesity, and diabetes, an elevated ApoB/ApoA-I
ratio was the strongest predictor of myocardial infarction
(27). In the AMORIS (Apolipoprotein-Related Mortality
Risk) study, a Swedish prospective study of 175,000 sub-
jects, ApoB and ApoB/ApoA-I ratio were found to be
superior to LDL-C levels in predicting cardiovascular risk,
especially in the stratum of patients with normal LDL-C
levels (31). These findings are consistent with the recent
results of the Emerging Risk Factors Collaboration trial that
showed that ApoB and Apo-AI improve cardiovascular risk
stratification especially in individuals classified at interme-
diate risk (10% or20% predicted 10-year risk) (32). In the
present study including a series of patients where 87% of
patients had an LDL-C level of 130 mg/dl
(3.37 mmol/l), the ApoB/ApoA-I ratio was a strong
Figure 1 Multivariable Predictors of Bioprosthetic Valve Degen
The risk of bioprosthetic valve degeneration was increased by 1.41-fold per 0.1 U
after adjustment for age and follow-up duration.predictor of SVD.Bisphosphonates and SVD. Conflicting results have been
reported concerning the association of bisphosphonates and
calcific aortic valve disease (33,34). In the present study,
bisphosphonate therapy was associated with SVD of BPVs,
and this association persisted after adjustment for age and
sex. Further studies are needed to examine the relationship
between dysregulation of mineral metabolism and SVD of
BPVs and to determine whether bisphosphonate therapy
has a direct positive or negative effect on SVD and whether
this effect is age-dependent as in native aortic valve disease.
Potential mechanisms underlying the association between
lipoproteins and SVD. For years, degeneration of BPVs
was seen as a purely passive mechanism, which was to a large
extent related to the chemical fixative treatment of porcine
or bovine tissues (1). This hypothetical model proposed that
the fixative treatment with glutaraldehyde prior to BPV
implantation combined to the repetitive mechanical stress
after implantation induced nucleation and growth of hy-
droxyapatite crystals (1).
However, recent histological studies of failed BPVs ex-
planted at reoperation also reported the presence of inflam-
matory cells, foam cells, ApoB, and oxidized lipids, as well
as expression of metalloproteinases within BPV tissues
(5,6). These findings suggest that similarly to native aortic
valve stenosis, a lipid-mediated inflammatory process could
contribute, at least in part, to the SVD of BPVs (22). The
infiltration of LDL particles within the BPV tissues and
their oxidation may trigger an inflammatory process and the
formation of foam cells (6,22). In turn, the inflammatory
cytokines and oxidized LDLs may induce active mineral-
ization and disruption of extracellular matrix, thereby lead-
ing to BPV stenosis and/or regurgitation.
The infiltration and oxidation of LDL particles within
the vascular and valvular tissues appears to be more closely
related to the number, size, and density of LDL particles
rather than to the total plasma concentration of LDL-C per
se (6,35,36). Indeed, the small dense LDL particles are the
n
se in the ApoB/ApoA1 ratio and by 3.57-fold with the use of bisphosphonate,eratio
increamost atherogenic because they persist in circulation for a
m
N
t
a
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within the arterial and valvular tissues, and have a high
susceptibility to oxidation. In native aortic valve stenosis, the
proportion of small, dense LDL particles was the only blood
metabolic marker found to correlate with the amount of
oxidized LDL deposited within the valve tissue (36). In a
recent retrospective study (37), we also found a significant
association between the prevalence of BPV hemodynamic
dysfunction and increased proportion of small LDL parti-
cles. In the present study, the concentration of LDL-C
255 Å was significantly associated with SVD. Further-
more, the phenotype of HDL particles may alter their
anti-atherogenic effects, regardless of the total plasma con-
centration of HDL-cholesterol. Hence, abnormal pheno-
types of LDL and/or HDL particles, as reflected by in-
creased ApoB/ApoA-I ratio, could enhance the production
of oxidized LDLs within the BPV tissues and thus promote
inflammatory and calcifying processes leading to SVD.
Viscerally obese individuals often develop insulin resis-
tance and an atherogenic dyslipidemia characterized by an
increased proportion of small, dense LDL and HDL
particles. These individuals may thus be at higher risk for
SVD, as suggested by previous retrospective studies (12,25).
In the present study, we found that the presence of the
metabolic syndrome was the most powerful determinant of
increased ApoB/ApoA-I ratio. Nonetheless, the ApoB/
ApoA-I ratio remained a significant independent predictor
of SVD even after adjustment for metabolic syndrome and
type II diabetes.
Clinical implications. SVD is the main cause of valve-
related morbidity and mortality in patients with BPVs.
There was until now no medical treatment to prevent the
development of SVD. An increased ApoB/ApoA-I ratio
may be useful to identify the patients who may be at higher
risk for SVD. Further studies are needed to determine if the
imbalance between proatherogenic and antiatherogenic li-
poproteins reflected by increased ApoB/ApoA-I contributes
directly to SVD or whether it is simply a marker for other
risk factors. Nonetheless, when analyzing collectively the
data presented in this study as well as those reported in
previous studies (12,25), the main factors that have been
found to be independently associated with increased risk of
SVD (i.e., metabolic syndrome, diabetes, increased ApoB/
ApoA-I ratio) are, at least in part, related to visceral obesity
and ensuing insulin resistance. Hence, aggressive changes in
lifestyle, including increase in physical activity and imple-
mentation of dietary changes (38), should probably be
considered as the first-line intervention for SVD prevention
in those patients with a BPV presenting with one or more
of these factors. On the other hand, specific pharmacolog-
ical therapies directed toward visceral obesity, metabolic
syndrome, diabetes, or the associated atherogenic dyslipide-
mia will need to be supported by further mechanistic studies
and validated in future randomized clinical trials. One of the
advantages inherent to this particular context is that, as
opposed to patients with native aortic valve disease, the apharmacological treatment could be instituted at the time of
AVR before the initiation of the pathologic processes
leading to SVD. This study also revealed that the associa-
tion between ApoB/ApoA-I persisted after adjustment for
metabolic syndrome and diabetes, which suggest that other
factors may modulate the ApoB/ApoA-I ratio and the
associated risk of SVD.
Statin drugs have been shown to decrease ApoB by 15%
to 40% and increase ApoA-I by 5% to 15%; therefore,
decreasing the ApoB/ApoA-I ratio by 25% to 45%
(26,39,40). Consistently, in the present study, statins were
independently associated with decreased ApoB/ApoA-I
ratio. However, 77% of patients were taking statins in the
present study, and there was no evidence of significant
protective effect of such therapy with regard to SVD. In
patients with native aortic valve stenosis and normal cho-
lesterol levels, three randomized trials (SALTIRE [Scottish
Aortic Stenosis and Lipid Lowering Trial], SEAS [Sim-
vastatin and Ezetimibe in Aortic Stenosis] trial, and
ASTRONOMER [Aortic Stenosis Progression Observa-
tion: Measuring Effects of Rosuvastatin] trial) failed to
demonstrate a significant effect of statins on stenosis
progression and clinical outcomes (41– 43).
As for BPV degeneration, one retrospective study in 167
patients reported that statin therapy reduced the develop-
ment of SVD (24). Other retrospective studies in larger
series of patients, however, have failed to demonstrate a
benefit for statin therapy in the prevention of SVD
(12,25,44).
The main limitation of these studies of patients with
BPV, including the present investigation, is that they are
non-randomized and their results may thus have been
affected by: 1) the inherent differences between the patients
treated with statins versus those without statins; and 2) the
inter-individual variability in the timing of initiation and in
the duration of statin therapy.
Study limitations. The present study is a prospective
cross-sectional study that reported the prevalence of SVD at
the time of the study. Most patients did not have serial
echocardiographic follow-up. Hence, the information about
the exact timing of SVD onset is unknown. In addition, the
blood metabolic data were obtained at the time of the study
(i.e., at last echocardiographic follow-up, which limits the
inferences with regards to the value of the ApoB/ApoA-I
ratio at the time of surgery to predict future development of
SVD). The apparent lack of significant association between
SVD and some clinical factors, including metabolic syn-
drome, diabetes, and statin therapy, may be a type II error
because of the relatively small sample size. Given the small
number (n  45) of patients with SVD, some of the
ultivariate logistic regression models were overfitted.
onetheless, this limitation does not affect the validity of
he main result of this study, which is the demonstration of
strong association between increased ApoB/ApoA-I rationd SVD.
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This is the first study to report a strong association between
increased ApoB/ApoA-I ratio and the risk of SVD. These
findings support the concept that SVD is not a passive
degenerative process but rather an active multifaceted pro-
cess, which includes lipid-mediated mechanisms leading to
mineralization and/or disruption of BPV tissues. Further
studies are needed to determine if increased ApoB/ApoA-I
ratio, which reflects the balance of pro-atherogenic and
anti-atherogenic lipoproteins, is simply a risk marker or
rather a true risk factor for SVD. Nonetheless, the findings
of the present study can be used to generate the hypothesis
that the initiation at the time of aortic valve replacement of
aggressive changes in lifestyle and/or specific pharmacolog-
ical therapy aiming at reduction of ApoB/ApoA-I ratio
might help to reduce the incidence of SVD.
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